Agios Pharma (AGIO) Misses Q4 EPS by 10c

Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.72), $0.10 worse than the analyst estimate of ($1.62). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $7.94 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Morgan Stanley backs Yum Brands, cuts Chipotle rating as growth outlook diverges
• Veeva Systems (VEEV) Tops Q1 EPS by 10c, Offers Guidance